Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8638826 | 0.98 | PTGS2 (0.49) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL8641577 | 0.90 | PTGS2 (0.49) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL8640765 | 0.90 | PTGS1 (0.51) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL6520780 | 0.89 | PTGS2 (0.48) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL6515865 | 0.88 | PDPK1 (0.45) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL8351386 | 0.88 | PTGS2 (0.49) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL8639795 | 0.87 | PTGS2 (0.50) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL8638817 | 0.87 | PTGS2 (0.46) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL6514097 | 0.87 | PTGS2 (0.50) | PTGS2PDPK1PTGS1RXRANR1H2 | |
| SCHEMBL7135445 | 0.87 | PTGS2 (0.51) | PTGS2PDPK1PTGS1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | claimed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | claimed |
| EP-1086097-B1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | claimed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | claimed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | claimed |
| US-6949536-B2 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1086097-B1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6727238-B2 | CYCLOOXYGENASE INHIBITORS | PFIZER INC. | 2004-04-27 | — | — | US | disclosed |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2003-12-04 | — | — | US | disclosed |
| US-6608095-B2 | Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens | PFIZER INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | ANDO KAZUO (JP) | 2002-04-18 | — | — | US | disclosed |
| US-6294558-B1 | ANTIINFLAMMATORY AGENTS AND PROSTAGLANTINS | PFIZER INC. | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | PTGS2 29/4885PDPK1 3634/4885PTGS1 2/4885 |
| US-20020045654-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGER1, PTGS1 | PTGS2 30/4885PDPK1 3912/4885PTGS1 3/4885 |
| US-20030225064-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | PTGS2 29/4885PDPK1 3634/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.